Mounjaro Clinics Near Me - Find a Mounjaro Prescriber in Your State

What Is Mounjaro?

Mounjaro is the brand name for tirzepatide 2.5mg-15mg weekly injection, developed by Eli Lilly and FDA-approved in 2022 for the treatment of type 2 diabetes. It is the world's first dual GIP and GLP-1 receptor agonist - meaning it activates two hormone pathways simultaneously, which produces significantly greater blood sugar control and weight loss than single-agonist GLP-1 drugs like semaglutide.

In the SURPASS clinical trial program, Mounjaro reduced HbA1c by up to 2.4% and produced 12-25 lbs average weight loss in diabetic patients - substantially outperforming Ozempic in head-to-head comparisons. For weight management specifically, Eli Lilly markets tirzepatide under the brand name Zepbound (approved 2023).

Mounjaro is administered as a once-weekly subcutaneous injection and requires physician oversight including periodic lab monitoring.

Who Considers Mounjaro?

• Adults with type 2 diabetes seeking superior blood sugar control beyond what GLP-1 drugs alone provide
• Patients who tried Ozempic or other semaglutide medications and want greater efficacy
• People with obesity or overweight plus type 2 diabetes
• Those interested in the dual GIP/GLP-1 mechanism and its metabolic benefits

What to Expect at a Consultation

A Mounjaro consultation will cover your diabetes history, current blood sugar control, HbA1c, medications, and weight. Your physician will determine the appropriate starting dose (2.5mg) and titration plan (increasing by 2.5mg every 4 weeks as tolerated up to 15mg). If you do not have a diabetes diagnosis but are interested in tirzepatide for weight loss, your physician may prescribe Zepbound instead. Many telehealth programs offer both with pharmacy coordination.